Thyrocare Technologies Ltd
Thyrocare Technologies Ltd (THYROCARE) last reported results for the quarter ended Jun 2026, with sales of ₹240 crore and net profit of ₹51 crore. The next scheduled event is a merger acquisition on 2 Nov 2026. The stock last traded at ₹538, a market capitalisation of ₹8,561 crore, on a P/E of 47.4. Over the past 52 weeks the stock has ranged between ₹343 and ₹662. Figures are as of 6 Oct 2026 and are not real time.
Thyrocare Technologies Ltd share price and key metrics
- Current price
- ₹538
- Market cap
- ₹8,561 cr
- Stock P/E
- 47.4
- Book value
- ₹36.8
- ROE
- 28.4%
- ROCE
- 35.4%
- Dividend yield
- 1.72%
- 52w high / low
- 662/343
Metrics as of 6 Oct 2026. Not real time.
Track Thyrocare Technologies Ltd
Cruxal reads every Thyrocare Technologies Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Thyrocare Technologies Ltd growth and returns
- 10 Years
- 13%
- 5 Years
- 11%
- 3 Years
- 16%
- TTM
- 21%
- 10 Years
- 12%
- 5 Years
- 8%
- 3 Years
- 36%
- TTM
- 70%
- 10 Years
- 10%
- 5 Years
- 7%
- 3 Years
- 42%
- 1 Year
- 34%
- 10 Years
- 21%
- 5 Years
- 20%
- 3 Years
- 20%
- Last Year
- 28%
Thyrocare Technologies Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹240 cr, up 24.4% from ₹193 cr a year earlier. Net profit was ₹51 cr, up 34.2% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 177 | 166 | 187 | 193 | 217 | 196 | 224 | 240 |
| Expenses | 129 | 124 | 130 | 135 | 145 | 138 | 149 | 163 |
| Operating profit | 48 | 42 | 57 | 58 | 71 | 58 | 75 | 77 |
| OPM % | 27% | 25% | 30% | 30% | 33% | 30% | 34% | 32% |
| Other income | 3 | 4 | 5 | 5 | 3 | -1 | 5 | 5 |
| Interest | 1 | 1 | 1 | 1 | 1 | -0 | 2 | 1 |
| Depreciation | 13 | 17 | 14 | 11 | 12 | 22 | 14 | 12 |
| Profit before tax | 37 | 28 | 47 | 50 | 63 | 35 | 64 | 68 |
| Tax % | 28% | 32% | 54% | 24% | 24% | 21% | 24% | 25% |
| Net profit | 26 | 19 | 22 | 38 | 48 | 28 | 49 | 51 |
| EPS (₹) | 1.68 | 1.20 | 1.36 | 2.45 | 3.02 | 1.82 | 2.96 | 3.28 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Thyrocare Technologies Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 304 | 356 | 403 | 434 | 495 | 589 | 527 | 572 | 687 | 829 | 876 |
| Operating profit | 115 | 145 | 154 | 174 | 171 | 236 | 123 | 140 | 190 | 263 | 282 |
| OPM % | 38% | 41% | 38% | 40% | 35% | 40% | 23% | 24% | 28% | 32% | 32% |
| Net profit | 43 | 93 | 85 | 88 | 113 | 176 | 64 | 69 | 91 | 163 | 176 |
| EPS (₹) | 2.66 | 5.79 | 5.38 | 5.58 | 7.13 | 11.10 | 4.06 | 4.45 | 5.76 | 10.24 | 11.08 |
TTM is the trailing twelve months to the most recent quarter.
Thyrocare Technologies Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 54 | 54 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 159 |
| Reserves | 354 | 390 | 382 | 314 | 374 | 474 | 481 | 474 | 494 | 426 |
| Borrowings | 0 | 0 | 2 | 12 | 8 | 21 | 23 | 42 | 25 | 51 |
| Other liabilities | 30 | 36 | 37 | 90 | 106 | 60 | 74 | 75 | 121 | 111 |
| Total liabilities | 438 | 479 | 475 | 469 | 541 | 607 | 632 | 644 | 693 | 747 |
| Fixed assets | 259 | 299 | 294 | 269 | 253 | 285 | 294 | 306 | 297 | 317 |
| CWIP | 17 | 0 | 1 | 5 | 8 | 3 | 2 | 3 | 14 | 3 |
| Investments | 104 | 120 | 95 | 90 | 126 | 146 | 144 | 162 | 162 | 177 |
| Other assets | 58 | 60 | 84 | 105 | 154 | 173 | 192 | 173 | 220 | 250 |
| Total assets | 438 | 479 | 475 | 469 | 541 | 607 | 632 | 644 | 693 | 747 |
As reported by the company. Total assets equal total liabilities by construction.
Thyrocare Technologies Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 90 | 107 | 100 | 168 | 115 | 113 | 129 | 168 | 191 | 213 |
| Cash from investing | -42 | -43 | -12 | 1 | -49 | -24 | -39 | -91 | -53 | -23 |
| Cash from financing | -49 | -64 | -94 | -165 | -62 | -89 | -86 | -85 | -130 | -170 |
| Net cash flow | -0 | -0 | -5 | 4 | 4 | 0 | 4 | -8 | 8 | 21 |
| Free cash flow | 53 | 63 | 61 | 158 | 93 | 99 | 88 | 107 | 146 | 198 |
| CFO / operating profit | 113% | 108% | 104% | 122% | 92% | 72% | 128% | 141% | 123% | 104% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Thyrocare Technologies Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 28% | 33% | 30% | 35% | 36% | 42% | 17% | 18% | 25% | 35% |
| Debtor days | 8 | 10 | 11 | 14 | 33 | 58 | 59 | 28 | 39 | 33 |
| Inventory days | 65 | 66 | 60 | 64 | 52 | 53 | 62 | 104 | 89 | 81 |
| Days payable | 6 | 25 | 25 | 68 | 56 | 36 | 54 | 88 | 146 | 109 |
| Cash conversion cycle | 67 | 50 | 46 | 10 | 29 | 75 | 67 | 44 | -18 | 4 |
| Working capital days | 19 | 10 | 28 | -8 | 19 | 41 | 31 | 7 | 13 | 19 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Thyrocare Technologies Ltd shareholding pattern
Promoters held 60.92% at Jun 2026, down from 71.06% at Jun 2025. FIIs 5.43% and DIIs 20.92%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 71.11% | 71.06% | 71.06% | 71.06% | 71.06% | 60.93% | 60.92% | 60.92% |
| FIIs | 1.93% | 2.77% | 2.41% | 3.23% | 4.85% | 4.96% | 5.37% | 5.43% |
| DIIs | 14.79% | 14.68% | 14.97% | 14.54% | 13.47% | 20.52% | 21.00% | 20.92% |
| Public | 12.15% | 11.49% | 11.57% | 11.18% | 10.61% | 13.61% | 12.71% | 12.71% |
| No. of shareholders | 59,377 | 56,666 | 57,403 | 54,566 | 54,142 | 77,619 | 73,377 | 73,064 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Thyrocare Technologies Ltd events
The next scheduled event is a merger acquisition on 2 Nov 2026.
- Merger acquisitionDivestment of entire shareholding in material subsidiary Nueclear Healthcare Limited to Trovera Healthcare Private Limited
- Merger acquisitionDivestment of entire shareholding in subsidiary Nueclear Healthcare Limited
See the full results calendar for every Indian company reporting in the next 30 days.
Thyrocare Technologies Ltd corporate filings
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find attached herewith Certificate pursuant to Regulation 74(5) of the SEBI…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
- Thyrocare Technologies to divest material subsidiary Nueclear Healthcare for INR 141.4 croreAGM/EGMhigh impact
Cruxal's analysis: Thyrocare Technologies Limited has announced a strategic divestment of its entire 100%…
Read the full analysis - Thyrocare Technologies Ltd announces grant of employee stock optionsCompany Updatelow impact
Cruxal's analysis: Thyrocare Technologies has issued an intimation regarding the grant of options under its…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: Please find attached the Intimation for Closure of Trading Window
Read the full analysis - Thyrocare Technologies to divest entire stake in material subsidiary Nueclear Healthcare LimitedCompany Updatemedium impact
Cruxal's analysis: Thyrocare Technologies has announced the proposed sale of its entire shareholding in its…
Read the full analysis - Thyrocare Technologies to divest radiology subsidiary Nueclear Healthcare for Rs 141.40 croreCompany Updatehigh impact
Cruxal's analysis: Thyrocare Technologies Limited has announced the divestment of its entire 100% stake in…
Read the full analysis - Thyrocare Technologies: Promoter Pledge Released Following Full Redemption of INR 1,050 Crore NCDsInsider Trading / SASThigh impact
Cruxal's analysis: Thyrocare Technologies Limited has confirmed the full release of a pledge over 7.95 crore…
Read the full analysis - API Holdings Limited completes internal restructuring; acquires 51.02% stake in Thyrocare Technologies Limited via amalgamation of Docon TechnologiesInsider Trading / SASTlow impact
Cruxal's analysis: API Holdings Limited has successfully completed the amalgamation of its subsidiary, Docon…
Read the full analysis - Thyrocare Technologies Ltd publishes newspaper notices regarding regulatory complianceCompany Updatelow impact
Cruxal's analysis: Thyrocare Technologies Ltd has fulfilled its regulatory obligation under Regulation 30 of…
Read the full analysis - API Holdings Limited completes amalgamation of Docon Technologies, consolidating 51.02% stake in Thyrocare TechnologiesInsider Trading / SASTmedium impact
Cruxal's analysis: API Holdings Limited has announced the successful completion of the amalgamation of Docon…
Read the full analysis - Thyrocare Technologies announces NCLT approval for internal promoter group restructuring via amalgamation of Docon Technologies with API HoldingsCompany Updatelow impact
Cruxal's analysis: Thyrocare Technologies has received NCLT approval for the amalgamation of its promoter…
Read the full analysis - Thyrocare Technologies confirms full redemption of Non-Convertible Debentures by API Holdings LimitedOtherslow impact
Cruxal's analysis: Thyrocare Technologies has announced the complete discharge and release of transaction…
Read the full analysis - Thyrocare Technologies Limited: Full Release of Pledge on 7.95 Crore Equity Shares Following Debt RedemptionInsider Trading / SASThigh impact
Cruxal's analysis: Thyrocare Technologies Limited has announced the complete release of a pledge on 7 crore…
Read the full analysis - Thyrocare Technologies Promoter Docon Technologies Releases Pledge on 1.75 Crore SharesInsider Trading / SASTmedium impact
Cruxal's analysis: Docon Technologies Private Limited, the promoter of Thyrocare Technologies Limited, has…
Read the full analysis - Thyrocare Technologies: Promoter releases pledge on 7.95 crore shares following full debt repayment by API HoldingsInsider Trading / SASThigh impact
Cruxal's analysis: Thyrocare Technologies Limited has announced that its promoter, Docon Technologies…
Read the full analysis - HSBC Mutual Fund Increases Stake in Thyrocare Technologies Limited to 6.63%Insider Trading / SASTmedium impact
Cruxal's analysis: HSBC Mutual Fund has disclosed an acquisition of 29.99 lakh shares of Thyrocare…
Read the full analysis - Thyrocare Technologies: Promoter Docon Technologies Releases Pledge on 1.75 Crore Equity SharesInsider Trading / SASTmedium impact
Cruxal's analysis: Thyrocare Technologies Limited's promoter, Docon Technologies Private Limited, has…
Read the full analysis - Thyrocare Technologies: Promoter Docon Technologies Fully Releases Pledge on 7.95 Crore SharesInsider Trading / SASThigh impact
Cruxal's analysis: Thyrocare Technologies Limited's promoter, Docon Technologies Private Limited, has…
Read the full analysis - Thyrocare Technologies: Promoter Docon Technologies Fully Releases Pledge on 7.95 Crore SharesInsider Trading / SASThigh impact
Cruxal's analysis: Thyrocare Technologies Limited's promoter, Docon Technologies Private Limited, has…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.